Background: Suboptimal use of cardiovascular prevention medications has been reported. We report recent trends in secondary cardiovascular disease prevention drug use in Europe. Design: We used the 2004-2013 data from the Survey of Health, Ageing and Retirement in Europe (SHARE), a large longitudinal cohort study in middle-aged and elderly Europeans. Methods: Cross-sectional and panel data logistic regression models were used to study trends in cholesterol-and blood pressure-lowering drug use and effects of participant characteristics on the likelihood of drug use among participants with histoty of cardiovascular disease in SHARE. Results: In SHARE 21,388 participants reported history of cardiovascular disease and provided data on cholesterol-and blood pressure-lowering drug use. At initial report, 40% and 60% of them used cholesterol-or blood pressure-lowering drugs, respectively. Increasing cross-sectional time trends were observed for both medication classes (odds ratios of use in 2013 vs. 2004, 1.6 (95% confidence interval 1.4-1.7) and 1.5 (1.4-1.6), respectively). However, among participants with multiple observations, the use of both classes declined over time (2013 vs. 2004 odds ratio 0.63 (0.51-0.77) and 0.68 (0.55-0.84), respectively; both trend p < 0.001), and with increasing duration since last cardiovascular event (odds ratio 0.74 (0.60-0.91), trend p ¼ 0.01 and odds ratio 0.82 (0.66-1.03), trend p ¼ 0.06, respectively for durations of nine years or more versus less than one year). Among people with history of cardiovascular disease, those obese, retired or with hypercholesterolaemia, hypertension, worse self-perceived health, and, in the case of lipid-lowering medication, with diabetes, were more likely to use these medications. Conclusions: Despite moderately increasing cross-sectional time trends, the use of secondary cardiovascular disease prevention drugs remains low in Europe with substantial discontinuation over time and with increasing duration from an acute cardiovascular event.
Introduction
For people who have suffered a myocardial infarction or stroke, ample evidence and clinical guidelines support the use of cholesterol-and blood pressure (BP)-lowering drugs to reduce increased risks of further cardiovascular events. 1, 2 However, suboptimal use of these medications has been reported in such populations. 3, 4 A European multi-national cross-sectional study reported national levels of use of cholesterol-lowering medications about one year after admission to hospital with an acute coronary event ranging from 74% to 96% for statins, for b-blockers from 68% to 94%, and for ACE inhibitors/angiotensin II receptor-blockers from 49% to 87% in 2012-2013. 5 A study of 2007-2010 drug-dispensing records in the Netherlands found that three years after hospital admission for an acute coronary syndrome (ACS) merely 53%, 50% and 57% used lipid-lowering, b-blockers and other BP-lowering drugs, respectively. 6 Variation in use has been reported across gender, age, health and socio-economic status. 3, 6, 7 However, ways of identifying individuals likely to not initiate or to discontinue therapy and strategies to improve use of preventive medications remain understudied. 8 We report recent trends in cholesterol-and BP-lowering drug use for secondary cardiovascular disease (CVD) prevention in middle-aged and older Europeans and factors associated with suboptimal use.
Methods

The Survey of Health, Ageing and Retirement in Europe (SHARE)
SHARE's design and sampling frame aimed to recruit and follow representative national population samples. Individuals aged 50 or older and their spouses were recruited from 20 European countries and followed in waves 1 (2004-2006) , 2 (2007-2009 ), 4 (2010-2012) and 5 (2013) . Trained personnel led face-to-face computerassisted personal interviews and conducted anthropometric examinations of the participants during each study wave and data were collected on socio-economic, health and wellbeing factors including medication intake, history of onset of chronic conditions, healthrelated behaviours and cognitive factors. Further details of the design, survey methods and population characteristics are reported in the Supplementary Methods online. 9 
SHARE participants with history of CVD
For the current analysis, we identified all SHARE participants with self-reported history of doctor-diagnosed CVD. Throughout the study, participants were asked, 'Has a doctor ever told you that you had any of the conditions . . .?' followed by a list of common chronic diseases including heart attack (i.e. myocardial infarction, coronary thrombosis and congestive heart failure) and stroke or cerebral vascular disease. At each subsequent study interview, participants were also asked if they had suffered a heart attack or stroke since their last interview. Report of any of these conditions was used to determine history of CVD (Supplementary Table 1 online).
Outcomes
Throughout the study, participants provided information on whether they were taking drugs at least once a week for: (i) high blood cholesterol, (ii) high BP, (iii) coronary or cerebrovascular diseases, and (iv) other heart diseases. Two (binary) main outcome variables were established: (i) self-reported use of cholesterollowering drugs and (ii) self-reported use of BP-lowering drugs. To assess the impact of potential misclassifications of CVD medications owing to self-reports, a third outcome variable summarising use of any cardiovascular medication (the above two categories plus any drug for coronary, cerebrovascular or other heart disease) was used in sensitivity analyses.
Statistical analyses
First, the relevance of a range of participant characteristics to the likelihood of use of cholesterol-or BP-lowering medication was estimated at participants' initial report of CVD in SHARE using logistic regression models and adjusting for current age, gender, education and participant country. Second, cross-sectional time trends across study waves (i.e. each wave was considered an independent data snapshot of medication use) were estimated within participating countries, within categories of countries by higher-or lowermedian gross national income (GNI) (with a threshold of $29,460 (purchasing power parity-adjusted in current international dollars) in 2004 10 ) and across all participating countries using logistic regression models. The Wald test for heterogeneity or, if appropriate, trend in drug use between categories of participants was used after adjustment for current age, gender, education and participant country as relevant. 11 Third, the importance of (i) between-participant variation and (ii) within-participant variation in medication use was investigated using the longitudinal SHARE data. Multivariate panel data logistic regression models were estimated including statistically significant participant characteristics from the initial logistic regressions (with current age, gender, education and country preserved independently of statistical significance). Such participant characteristics included marital status, history of hypercholesterolaemia, hypertension, diabetes or other chronic conditions, time duration since latest heart attack or stroke, body mass index (BMI), alcohol consumption, smoking, physical exercise, employment, cognitive function, self-perceived health, education, household equivalised income and residential area (for variable definitions see Supplementary 12 Sensitivity analyses studied whether the results differed between higher-and lower-GNI countries. The impact of possible misreporting of the type or purpose of any used cardiovascular medication was investigated by evaluating relevance of participant characteristics to the reported use of any cardiovascular drug, as well as to the reported combined cholesterol-or BP-lowering drug use.
All statistical analyses were performed with Stata (version 12, Stata Corp., USA).
Results
Study population
One hundred and nine thousand individuals from 20 countries were recruited and followed between 2004 and 2013, of whom 21,388 (20%) reported history of CVD at some point during the study (16% reported heart attack and 5% stroke) and provided data on use of cholesterol-and BP-lowering drugs. Of these participants, 8431 (39%) were interviewed only once and 12,957 (61%) at least twice (39%, 12% and 10% were interviewed twice, thrice and four times, respectively). The mean age at first report of CVD (i.e. baseline) was 72 years (SD 10) and 52% were male (Table 1) . At baseline, participants reported that they had had CVD for a median of 7 (IQR 2-15) years and had had their latest heart attack or stroke at a median of 6 (IQR 1-14) years previously; 37% and 57% reported having been told by their doctor that they had high cholesterol or high BP, respectively.
Self-reported use of cholesterol-and BP-lowering medication at initial CVD report in SHARE Overall, 8509 (40%) and 12,909 (60%) of the 21,371 participants with history of CVD and available drug use data reported they were using cholesterol-or BPlowering medication, respectively, at baseline (Table 1) . Compared with non-users, users of cholesterol-or, separately, BP-lowering drugs were more likely to be overweight or obese (both trend p < 0.001 for BMI > 18.5 kg/m 2 ), retired (both heterogeneity p < 0.001), to have diabetes (both p < 0.001) or other comorbidities (both trend p < 0.001 across categories of other comorbidities) and to not be a current smoker (both heterogeneity p < 0.001). Users of cholesterol-lowering drugs were also less likely to be elderly (trend p < 0.001) or female (37% vs. 42%; p < 0.001), while the opposite was observed for users of BP-lowering drugs (trend p < 0.001 across age categories; 64% use in women vs. 57% in men, p < 0.001). However, the strongest cross-sectional associations were observed between history of high cholesterol and use of cholesterol-lowering drugs (79% vs. 16%, p < 0.001) and between history of high BP and use of BP-lowering drugs (90% vs. 20%, p < 0.001; Table 1 ).
Cross-sectional trends in self-reported use of cholesterol-and BP-lowering drugs between 2004 and 2013
After adjustment for participants' age, gender and education, increasing cross-sectional trends in use of cholesterol-and BP-lowering drugs between 2004 and 2013 were observed in most participating countries ( Table 2) . These trends were significant across all participating countries (odds ratio (OR) 1.6 (95% confidence interval (CI) 1.4-1.7) for cholesterol-lowering drug use and 1. 
Participant characteristics associated with selfreported cholesterol-and BP-lowering drug use: longitudinal cohort panel data analysis
The Hausman tests did not support the hypothesis that the differences in coefficients between fixed-and random-effects panel data logistic models were not systematic (p < 0.001 for both cholesterol-and BP-lowering drug use), and the fixed-effects panel data model was indicated to account for possible time-invariant confounding.
The results of the longitudinal fixed-effects panel data logistic regression models (Table 3) Table 2 . Use of cholesterol-and BP-lowering drugs among participants with history of cardiovascular disease in SHARE (N ¼
21,388).
Cholesterol-lowering drug users n (%) 111 (33) 271 (45) 444 (45)
<0.001
168 (53) 183 (54) 387 (64) 596 (60) 0.01
Total 1763 (39) 2641 (41) 4442 (40) 5432 (42)
2402 (53) 3811 (59) 7040 (63) 8080 ( Table 2 ). Compared with those of normal weight, obese participants (BMI 30) were more likely to take cholesterol-(OR 1.38 (95% CI 1.02-1.86)) and BP-lowering drugs (OR 1.52 (1.12-2.08); Table 3 ). Similarly, participants with poorer self-perceived health had a higher propensity to use cholesterol-(OR 1.84 (95% CI 1.49-2.29)) and BP-lowering drugs (OR 2.25 (1.82-2.79)) compared with those rating their health as excellent or very good. Participants aged 68-77 were more likely to use cholesterol-lowering drugs than younger participants (OR 1.32 (1.08-1.62)). Retirement was associated with an increase in usage of both medications (cholesterol-lowering drug use: OR 1.96 (95% CI 1.49-2.57); BP-lowering drug use: OR 1.80 (1.35-2.40)) independently of age. Diagnosis of diabetes was associated with increased odds of cholesterollowering drug use (OR 1.57 (95% CI 1.21-2.05)); however, an increasing number of other comorbidities did not affect drug use. Changes in cognitive function, alcohol consumption, smoking behaviour, frequency of physical exercise, marital status, and household income were not associated with changes in drug use. No differences in drug use were observed between rural versus urban residences.
In the sensitivity analysis, while the temporal trends for use of any cholesterol-or BP-lowering medication remained positive (Supplementary Table 3) , there was no evidence for cross-sectional temporal trends in use of any cardiovascular drug (Supplementary Table 4 ). The longitudinal fixed-effect panel data model of use of any cardiovascular drug produced results largely consistent with the results for cholesterol-and BP-lowering drug use, with even stronger trends of decreasing medication use within individuals with increasing duration since the latest cardiovascular event. The associations of hypercholesterolaemia and hypertension with any cardiovascular medication use were much weaker compared with associations with cholesterol-or BPlowering drug use (Supplementary Table 5 ).
Discussion
In this longitudinal, community-based study of use of cholesterol-and BP-lowering drugs for secondary CVD prevention in a middle-aged and elderly European population, cross-sectional analyses showed that the use of both categories of medication was low (40% and 60%, respectively, at initial CVD report) and increased only moderately from 2004 to 2013. Further analysis among participants with multiple observations showed that the use of both drug categories declined (i) over time, and (ii) with an increasing number of years since the latest cardiovascular event. History of doctor-diagnosed hypercholesterolaemia and hypertension were the strongest predictors of usage of cholesterol-and BP-lowering medications, respectively. Retirement, low self-perceived health, diabetes and obesity were positively associated with medication use.
Since the late 1990s, (inter)national clinical guidelines have progressively recommended a shift away from cholesterol and BP levels as factors determining the need for preventive CVD drug treatments and towards an approach targeting absolute cardiovascular risk. [13] [14] [15] [16] Our study in a large community-based middle-aged and elderly European population draws a picture of preventive cardiovascular drug use and complements other survey data. 17 Its longitudinal nature allowed us to study factors associated with suboptimal preventive drug use and, with one-third of the participants aged 77 years or older, the study also provides valuable insights into the understudied elderly population.
The perceived disease risk appears an important factor even in a population with established CVD. While, independently of their cholesterol and BP levels, virtually all participants should be treated to prevent further CVD events, those participants with doctor-diagnosed hypertension or hypercholesterolaemia had a 4.5 and 4.6 times greater probability of being on BP-and cholesterol-lowering medications, respectively, than people with CVD but without such conditions. Similar observations have been made in a Chinese CVD population, 18 an international survey 4 and a US coronary disease population. 19 Furthermore, individuals with good self-perceived health, without diabetes, still in employment and/or not obese were less likely to use drugs despite having established CVD. However, our study data does not allow distinguishing between suboptimal prescribing and individuals' lack of compliance.
We found evidence for increasing cross-sectional time trends of cholesterol-and BP-lowering drug usage both in lower-and higher-income European countries. The probability of being on cholesteroland BP-lowering medication increased from 34% and 54% in 2004-2006 to 43% and 63% in 2013, respectively. The EUROASPIRE surveys in individuals about one year post an acute coronary hospital admission showed that between 2006 and 2013, crude statin and b-blocker use rose from 78% to 86% and from 80% to 83%, respectively. 5, 20 A population-based study of dispensing records in the Netherlands also found drug use at three years after discharge for ACS increased from 36% to 53% for lipid-lowering drugs and from 41% to 50% for b-blockers between 1998 and 2007. 6 These positive trends at the macro-level suggest that clinical guidelines have been progressively translated into practice. However, large variations still exist between countries, with those with lower GNI making slower progress than their wealthier counterparts.
The likelihood of discontinuing use of cardiovascular medication at the individual level is worrisome. Individuals in our study appear to increasingly discontinue treatment over time as well as with increasing duration since their latest cardiovascular event. The usage rates in the study about six years after an event are also substantially lower than rates in the EUROASPIRE survey about one year after an acute event. Other studies have also reported diminishing use of these medications with increasing time from initiation. A study of separate, population-based cohorts with acute and chronic coronary disease reported that only 40% and 36%, respectively, were adherent to statin therapy two years following treatment initiation, 21 while the proportion of the medication-adherent elderly population declined to 32% 10 years after statin initiation in another study. 22 While effective and affordable methods to improve adherence to medication regimens and to clinical guidelines are required, there is a striking lack of evidence of effective and cost-effective interventions, and most such experimental studies have too short follow-up periods to evaluate long-term outcomes. 23 A number of possible study limitations should be acknowledged. First, given the survey questions, it is not possible to differentiate between effects due to suboptimal medication prescribing and effects due to lack of compliance with prescribed medication. Second, the survey question regarding prior heart disease was broad and could include heart failure; however, we expect that the numbers with heart failure were relatively small. Finally, the use of categories of medication was derived from patient self-reports, which may be subject to misclassification. It cannot be excluded, for instance, that respondents regarded their cholesterol-or BP-lowering medication as cerebrovascular or other heart disease medication. However, any misclassification is likely to hold over time and within individuals and would be unlikely to bias our conclusions regarding impact of 
Conclusion
Health gains could be substantially increased with improved use of effective and widely available cholesteroland BP-lowering medications. Both physician-and patient-centred measures should be taken and more methodologically sound research and new strategies to improve adherence are needed.
